Literature DB >> 7448770

Growth and differentiation of human gastrointestinal adenocarcinoma stem cells in soft agarose.

C L Laboisse, C Augeron, F Potet.   

Abstract

A soft agarose clonogenic assay is presented which has been optimized for the growth of human gastrointestinal adenocarcinomas. Samples from 15 gastric and colonic solid tumors and from 2 noncancerous stomachs (control cultures) were disaggregated by treatment with collagenase at 37 degrees overnight. Colonies appeared 10 to 15 days after plating, with a cloning efficiency between 0 and 0.82%, which was markedly improved by a fibroblastic feeder layer. The results suggest a correlation between cloning efficiency and the degree of differentiation of the initial tumor. Histochemistry, electron microscopy, and a carcinoembryonic antigen immunofluorescence assay showed that the colonies consisted of cells with the same characteristics as those of the original tumor.. This colony formation assay appears to be potentially useful for assessing the stem cell pool of gastrointestinal tumors. It will be valuable for studying their response to chemotherapeutic agents in vitro. This clonogenic assay may also permit the establishment of cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7448770

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  The metalloproteinase ADAM-12 regulates bronchial epithelial cell proliferation and apoptosis.

Authors:  N Rocks; C Estrella; G Paulissen; F Quesada-Calvo; C Gilles; M M Guéders; C Crahay; J-M Foidart; P Gosset; A Noel; D D Cataldo
Journal:  Cell Prolif       Date:  2008-12       Impact factor: 6.831

2.  Clonal growth characteristics of adult human prostatic epithelial cells.

Authors:  D M Peehl; S T Wong; T A Stamey
Journal:  In Vitro Cell Dev Biol       Date:  1988-06

3.  Inhibited methionine incorporation in human squamous carcinomas of the oral cavity as a measure for response to 5-fluorouracil.

Authors:  T Görögh; J E Eickbohm; R Ewers; B Lippert; E E Holdener
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

4.  Cell kinetics and in vitro clonogenicity of primary colorectal cancer: clinicopathological relationships and the implications for chemotherapy.

Authors:  G A Trotter; G R Morgan; A J Cooper; N Kirkham; J M Whitehouse; I Taylor
Journal:  Gut       Date:  1985-03       Impact factor: 23.059

5.  Activity of cancer chemotherapeutic agents against human colorectal carcinomas grown as primary tissue culture.

Authors:  K A Zirvi; J van der Bosch; H Masui; N O Kaplan; G J Hill
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

6.  Relationship between histopathology and in vitro clonogenicity in breast cancer.

Authors:  J Moezzi; F Ali-Osman; G L Nicholson; J S Ungerleider; M J Murphy
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

7.  Methodologic problems in clonogenic assays of spontaneous human tumors.

Authors:  F R MacKintosh; T L Evans; B I Sikic
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

8.  RhoGDIα-dependent balance between RhoA and RhoC is a key regulator of cancer cell tumorigenesis.

Authors:  T T Giang Ho; Audrey Stultiens; Johanne Dubail; Charles M Lapière; Betty V Nusgens; Alain C Colige; Christophe F Deroanne
Journal:  Mol Biol Cell       Date:  2011-07-14       Impact factor: 4.138

9.  Mesothelial cells stimulate the anchorage-independent growth of human ovarian tumour cells.

Authors:  A P Wilson
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

10.  Differential roles of Hath1, MUC2 and P27Kip1 in relation with gamma-secretase inhibition in human colonic carcinomas: a translational study.

Authors:  Frédérique Souazé; Chantal Bou-Hanna; Christine Kandel; François Leclair; Julie Devallière; Béatrice Charreau; Stéphane Bézieau; Jean-François Mosnier; Christian L Laboisse
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.